Share
.webp)
.webp)
.webp)
.webp)
Angèle Maki
Ability Biotherapeutics, a biotechnology company developing logic-gated antibody therapies for cancer and autoimmune diseases, has appointed Angèle Maki, PhD, as Chief Business Officer.
In this role, Dr. Maki will lead the company’s business development and partnering strategy as Ability advances its innovative pipeline toward clinical development.
Dr. Maki brings more than 20 years of experience across the biopharmaceutical industry, with deep expertise in business development, licensing, and corporate venture activities. She has held senior leadership roles at several leading biotechnology and pharmaceutical organizations, including Medarex (now part of Bristol Myers Squibb), Genentech, Merck & Co., Eli Lilly and Company, and Callio Therapeutics. Her career spans both large global pharma and emerging biotech companies, giving her a broad perspective on building value through strategic collaborations and investments.
At Ability Biotherapeutics, Dr. Maki will be responsible for driving global partnering initiatives and expanding investor engagement to support the company’s growth objectives. Her efforts will focus on advancing Ability’s oncology and autoimmune programs developed using the company’s proprietary AbiLeap™ platform. Through strategic collaborations and financing activities, she will help unlock the platform’s potential to generate highly specific, logic-gated antibody therapies across multiple therapeutic indications.
Ability Biotherapeutics is building a growing pipeline of next-generation antibody therapeutics through its AbiLeap™ platform and is actively engaging with biotechnology and pharmaceutical partners. The company is open to collaborations supporting both pipeline program development and de novo therapeutic discovery. Dr. Maki, along with members of the Ability leadership team, will participate in the J.P. Morgan Healthcare Conference in January 2026 and welcomes discussions with potential partners and investors to further expand the company’s development and commercialization opportunities.
